Expert discusses how clinicians choose between FOLFIRINOX and newly approved NALIRIFOX for metastatic pancreatic cancer
Dr. Deirdre J. Cohen, director of GI Oncology at Mount Sinai, provides commentary on how doctors decide on frontline chemotherapy for metastatic pancreatic cancer.
She notes that, as of 2026, there is still no definitive biomarker to guide regimen choice, except for homologous recombination deficiency or DNA damage response alterations, which favor platinum‑containing therapies.
The two main options remain modified FOLFIRINOX and the newer NALIRIFOX, which received FDA approval in February 2024. Cohen compares their efficacy and discusses factors such as patient fitness and toxicity profiles.
Until more precise predictive tools are available, clinicians must weigh clinical characteristics and existing evidence when selecting between these regimens.
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer”
read at onclive ↗
comments(0)
5-min edit window · permanent after that